Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma

Yale J Biol Med. 2010 Mar;83(1):27-33.

Abstract

Vasoactive intestinal polypeptide secreting islet cell tumors (VIPomas) are neuroendocrine tumors that secrete excessive amounts of vasoactive intestinal polypeptide (VIP) that cause distinct syndromes characterized by large-volume diarrhea, hypokalemia, and dehydration. The annual incidence of these tumors is estimated to be about one per 10,000,000 individuals in the general population. We report a successful treatment of VIPoma with hepatic chemoembolization of a metastatic hepatic lesion evidenced by a reduction of VIP levels and resolutions of symptoms in a patient with pancreatic VIPoma unresponsive to increased doses of an octreotide analog.

Keywords: VIPoma; hepatic artery chemoembolization.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Embolization, Therapeutic*
  • Female
  • Hepatic Artery / pathology
  • Hepatic Artery / surgery*
  • Humans
  • Octreotide / therapeutic use*
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Treatment Outcome
  • Vasoactive Intestinal Peptide / metabolism*
  • Vipoma* / drug therapy
  • Vipoma* / physiopathology
  • Vipoma* / surgery

Substances

  • Antineoplastic Agents, Hormonal
  • Vasoactive Intestinal Peptide
  • Octreotide